Vivani’s GLP-1 implant achieves Phase 2 trial success by 2027 Q4
Resolves: Phase 2 trial results for NPM-139 show statistically significant improvement in weight maintenance compared to placebo or standard of care, with no major safety concerns raised.
user-generated· regulatory
Vivani’s GLP-1 implant achieves Phase 2 trial success by 2027 Q4
Market overview
Vivani Medical’s semaglutide implant, NPM-139, will demonstrate statistically significant weight maintenance in a Phase 2 clinical trial by December 31, 2027. Success in Phase 2 is a critical milestone to justify progression to larger-scale trials and regulatory discussions.
regulatory prediction market
- Implied probability (Yes)
- 55%
- Closes
- 2027-12-31
About this prediction
Resolution criteria
Phase 2 trial results for NPM-139 show statistically significant improvement in weight maintenance compared to placebo or standard of care, with no major safety concerns raised.
Source: user-generated
More regulatory markets
- Crypto billionaire Harborne faces FCA scrutiny over £5m gift — 55% Yes
- Crypto billionaire Harborne will face FCA scrutiny — 60% Yes
- Crypto billionaire Christopher Harborne’s donation triggers FCA inquiry into funding transparency — 70% Yes
- Crypto billionaire Christopher Harborne will face parliamentary scrutiny over £5m gift — 55% Yes
- Harborne crypto holdings face regulatory scrutiny — 60% Yes
- SEC approves at least 2 new Bitcoin ETFs by Q4 2027 — 75% Yes
- SEC approves Kalshi's crypto futures products by 2026-Q3 — 55% Yes
- Iran's central bank bans crypto mining by 2027 Q1 — 85% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…